Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Mind Medicine (MindMed) in a report issued on Tuesday, October 14th. Lifesci Capital analyst F. Brisebois forecasts that the company will post earnings of ($0.50) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Mind Medicine (MindMed)'s Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.88) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.22) EPS.
Several other brokerages have also commented on MNMD. Weiss Ratings restated a "sell (d-)" rating on shares of Mind Medicine (MindMed) in a research report on Wednesday, October 8th. Chardan Capital restated a "buy" rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, August 1st. Needham & Company LLC set a $28.00 target price on Mind Medicine (MindMed) and gave the company a "buy" rating in a research report on Monday. Finally, Oppenheimer began coverage on Mind Medicine (MindMed) in a research note on Monday, August 4th. They set an "outperform" rating and a $25.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $27.83.
Read Our Latest Report on MNMD
Mind Medicine (MindMed) Stock Up 0.3%
Shares of Mind Medicine (MindMed) stock opened at $12.66 on Thursday. Mind Medicine has a one year low of $4.70 and a one year high of $13.09. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.98 and a quick ratio of 4.98. The stock's 50-day moving average is $10.32 and its 200 day moving average is $8.23. The firm has a market cap of $963.30 million, a price-to-earnings ratio of -8.27 and a beta of 2.55.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.12).
Hedge Funds Weigh In On Mind Medicine (MindMed)
A number of large investors have recently made changes to their positions in MNMD. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Mind Medicine (MindMed) by 32.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,550 shares of the company's stock worth $94,000 after acquiring an additional 3,350 shares during the period. Rhumbline Advisers boosted its stake in Mind Medicine (MindMed) by 7.7% during the first quarter. Rhumbline Advisers now owns 108,457 shares of the company's stock valued at $634,000 after buying an additional 7,762 shares during the period. Janney Montgomery Scott LLC bought a new stake in Mind Medicine (MindMed) during the first quarter valued at $203,000. Palumbo Wealth Management LLC bought a new stake in Mind Medicine (MindMed) during the first quarter valued at $132,000. Finally, Oppenheimer & Co. Inc. boosted its stake in Mind Medicine (MindMed) by 8.5% during the first quarter. Oppenheimer & Co. Inc. now owns 71,115 shares of the company's stock valued at $416,000 after buying an additional 5,574 shares during the period. 27.91% of the stock is owned by institutional investors.
Insider Transactions at Mind Medicine (MindMed)
In other Mind Medicine (MindMed) news, insider Mark Sullivan sold 11,278 shares of the stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $9.77, for a total transaction of $110,186.06. Following the completion of the transaction, the insider directly owned 293,852 shares of the company's stock, valued at approximately $2,870,934.04. This represents a 3.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel Karlin sold 7,704 shares of the stock in a transaction on Thursday, September 25th. The shares were sold at an average price of $9.77, for a total value of $75,268.08. Following the transaction, the insider directly owned 430,625 shares of the company's stock, valued at approximately $4,207,206.25. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,779 shares of company stock valued at $437,491 over the last ninety days. 2.45% of the stock is currently owned by insiders.
Mind Medicine (MindMed) Company Profile
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.